News | January 24, 2014

First Uses of Veniti Vici Venous Stent System Reported??

Veniti Vici Venous Stent System Venous Therapies Clinical Study CE Mark
January 24, 2014 — Patients in the European Union (EU) received the first Veniti Vici Venous Stent System implants to treat symptomatic venous outflow obstruction of the lower extremities.
 
Stephen Black, a consultant vascular surgeon at St. George's Vascular Institute, St. George's Hospital, London, implanted Veniti Vici Stents in five patients on Jan. 14-15, 2014. 
 
"The Veniti Vici Venous Stent appears to have the radial strength and vein coverage to provide optimal results in patients with symptomatic outflow obstruction of the lower extremities," Black said. ??
 
The stent features including end-to-end crush resistance, radial resistive force, flexibility and continuous vein coverage. The Veniti Vici Venous Stent System has received CE marking and is seeking approval from the U.S. Food and Drug Administration (FDA) to begin clinical studies of the device in the United States. 
 
A live case demonstration at the Leipzig Interventional Course (LINC) is schedule for Jan. 28, 2014 in Leipzig, Germany.
 
The Veniti Veni RF Plus Endovascular Ablation System has also received CE marking. The Veniti?Vidi IVC Filter System is in early stages of clinical studies in New Zealand, and Veniti is seeking approval from the FDA to begin clinical studies of the device in the United States. 
 
For more information: www.veniti.com

Related Content

Biotronik Studies Demonstrate Efficacy of Minimizing Metal Burden in SFA Therapy
News | Stents Bare Metal| September 22, 2017
Physicians demonstrated that reducing metal burden in superficial femoral artery (SFA) therapy could effectively reduce...
Tryton Side Branch Stent Recognized With Premier Technology Breakthrough Award
News | Stents Bifurcation| September 21, 2017
September 21, 2017 — Cardinal Health and Tryton Medical Inc.
Abbott will end sales of the Absorb bioresorbable stent scaffold, pulling it off the market September 14, 2017.
Feature | Stents Bioresorbable| September 08, 2017 | Dave Fornell
September 8, 2017 — Abbott Vascular has announced it will end commercial sales of its Absorb bioresorbable vascular s
Biotronik's Orsiro Drug-Eluting Stent Outperforms Xience in BIOFLOW-V Trial
News | Stents Drug Eluting| September 01, 2017
September 1, 2017 — Biotronik recently announced data from the BIOFLOW-V randomized trial comparing Orsiro and Xience
FDA Approves Six-Month Primary Endpoint for Tack Endovascular System in Below the Knee Disease
News | Stents Peripheral| July 14, 2017
Intact Vascular Inc. announced the U.S. Food and Drug Administration (FDA) approved an Investigational Device Exemption...
ACCESS PTS Study Demonstrates Efficacy of EKOS Therapy for Post-Thrombotic Syndrome
News | Deep Vein Thrombosis| July 07, 2017
BTG plc recently highlighted the results of the ACCESS PTS trial, presented at the Society for Vascular Medicine 28th...
Sponsored Content | Videos | Venous Therapies| June 27, 2017
This video, provided by Ekos, demonstrates the EkoSonic endovascular System thrombolytic system to treat deep vein th
Onyx DES 2.0 mm stent meets primary endpoints in small vessels
News | June 12, 2017
June 12, 2017 – The Medtronic Resolute Onyx Drug-Eluting Stent (DES) met its primary endpoint of target lesion failur
First Pennsylvania Patient Treated in LEADERS FREE II Trial of BioFreedom Drug-Coated Stent
News | Stents Drug Eluting| May 12, 2017
PinnacleHealth CardioVascular Institute enrolled the first patient in Pennsylvania in a trial assessing the safety and...
Overlay Init